Ethismos is developing a novel smoking cessation medication with potentially higher efficacy than currently available medications. We hope to show reduced withdrawal effects, less impulsive smoking in response to behavioral cues, and less weight gain resulting in the possibility of less relapse
The initial phase 2 clinical program for smoking cessation is underway and combines nicotine replacement therapy (NRT) with amitifadine to address withdrawal, especially mood symptoms, the most frequent cause of smoking cessation failure (relapse).
The combination of currently available NRT and Ethismos therapies has potentially higher efficacy than standard medications, especially in heavy smokers who have failed in previous quit attempts.
The entire Ethismos team of scientists and researchers -along with our world renowned collaborators - are determined to develop safe and effective therapies that will help tobacco users break the chains and live healthier lives for themselves and their families.